Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Exp Hematol. 2011 Oct 20;40(1):22–34. doi: 10.1016/j.exphem.2011.10.003

Figure 2. A46 inhibits Jak2-V617F-dependent cell proliferation.

Figure 2

A. HEL cells were treated with either DMSO or 10 μM A46 for 0, 24, 48 or 72 hours. Viable cell numbers for each treatment were determined by trypan blue exclusion staining using a hemocytometer. Each sample was measured in triplicate. Shown is one of two sets of representative results. *p < 0.05 with respect to DMSO. B. HEL cells were treated with 10 μM A46 for 0, 8, 12, 24, 48 and 72 hours. At the end of each treatment, the cells were washed, placed in fresh medium and cultured in the absence of the inhibitor for an additional 72 hours. The number of viable cells in each sample was then determined. Each sample was measured in triplicate. Shown are the means ± S.E. from two independent experiments. HEL, SET-2, Raji and CMK cells were treated with increasing doses of A46 for 48 (C) or 72 (D) hours. The percent viable cells from each condition were determined either by trypan blue exclusion staining. Each sample was measured in triplicate.